CN103191162B - Application of fructus akebiae extract in preparation of drug for treating primary hepatic carcinoma - Google Patents
Application of fructus akebiae extract in preparation of drug for treating primary hepatic carcinoma Download PDFInfo
- Publication number
- CN103191162B CN103191162B CN201310140809.XA CN201310140809A CN103191162B CN 103191162 B CN103191162 B CN 103191162B CN 201310140809 A CN201310140809 A CN 201310140809A CN 103191162 B CN103191162 B CN 103191162B
- Authority
- CN
- China
- Prior art keywords
- fructus akebiae
- extract
- preparation
- drug
- hepatic carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses application of a fructus akebiae extract in preparation of a drug for treating primary hepatic carcinoma. The application is that the fructus akebiae extract is taken as an active ingredient to prepare a drug preparation for treating the primary hepatic carcinoma. A cancer cell growth and proliferation MTT (methyl thiazolyl tetrazolium) detection method is adopted by the invention, and the experiment demonstrates that the fructus akebiae extract has the significant effect of restraining malignant cell proliferation of the primary hepatic carcinoma, and is expected to be applied to preparation of the drug preparation for treating the primary hepatic carcinoma by restraining the malignant cell proliferation of the primary hepatic carcinoma; and a new medicinal value is opened up for the fructus akebiae extract.
Description
Technical field
The present invention relates to the application of a kind of Fructus Akebiae seed extract in treatment Primary Hepatic cancer drug, specifically, relate to the application of a kind of Fructus Akebiae seed ethanol extraction in the pharmaceutical preparation of preparation treatment primary hepatocarcinoma, belong to technical field of Chinese medicines.
Background technology
Fructus Akebiae another name Fructus Akebiae, August fried, August short, bristly hair or beard, Fructus Akebiae, August fruit, one hundred days melon, lead rattan melon, cured melon, draw fruit, Caulis Akebiae son, son of helping get over a shock, poultry Weed, by son, small wooden raft Im, cover son, cold meal bag, open country perfume friendship, YANGKAIKOU, be plants of Lardizabalaceae Caulis Akebiae (Akebia quinata(Thunb.) Decne.), threeleaf akebia (Akebia trifoliate(Thunb.) Koidz.), Caulis Akebiae (Akebia trifoliate(Thunb.) Koidz.var.australis((Diels)) Rehd.) and dry almost ripe fruit.Fructus Akebiae nature and flavor bitter cold, returns liver, gallbladder, stomach, urinary bladder channel; Depressed liver-energy dispersing and QI regulating, stomach function regulating, promoting blood circulation and stopping pain, hard masses softening and resolving, diuresis; For stagnation of liver-QI and stomach-QI, gastral cavity side of body distending pain, diet does not disappear, and dysentery is just let out, dysmenorrhea amenorrhea, hernia pain, sucutaneous nodule mass in the abdomen, the treatments such as dysuria.But, the discussion not about independent effect of Fructus Akebiae seed in prior art.
Up to now, the Fructus Akebiae form of the literature contents such as treatise, patent, scientific and technological achievement mainly with compound recipe composition one of medicine of being correlated with is main in clinical practice, and particularly clinical conventional effect Mechanism Study is rare in single medicinal material research; In those references, the prescription that Fructus Akebiae participates in repeatedly mentions Hepatoma therapy, but has no the study on mechanism report of its single medicinal material and single medicinal material.It is almost compound recipe clinical practice entirely that Fructus Akebiae Patents amounts to 132, only has in 1 single medicinal material Patents CN200910040491.1 and discloses a kind of Fructus Akebiae extract and preparation and its thereof purposes in antidepressant drug.For this liver cancer treatment Chinese medicine compound common medicine of Fructus Akebiae, its single medicinal material is applied to the research invention for the treatment of malignant tumor to having no relevant report at present.
Primary hepatocarcinoma is China's major disease, occupies mortality of malignant tumors the 2nd, and number of the infected accounts for 55% of the whole world, and serious threat people's life, causes family and social economical burden.But primary liver cancer there is no specific treatment method and medicine at present.Therefore, the cancer therapy drug finding determined curative effect is extremely urgent.The key of primary liver cancer genesis and development is the malignant proliferation that cancerous tumor cell can not regulate and control, and therefore effectively the propagation of anticancer is the key point of primary liver cancer.
By literature search, there is not yet Fructus Akebiae seed extract so far for suppressing the report of Primary hepatic carcinoma cell malignant proliferation and directly related disease aspect thereof.
Summary of the invention
The object of this invention is to provide a kind of new opplication of Fructus Akebiae seed extract.
A kind of new opplication of Fructus Akebiae seed extract provided by the invention refers to the pharmaceutical preparation using Fructus Akebiae seed extract as one of active component or sole active agent for the preparation for the treatment of primary hepatocarcinoma.
Described Fructus Akebiae seed extract is preferably the ethanol extraction of Fructus Akebiae seed.
As further preferred version, the ethanol extraction of described Fructus Akebiae seed is that the ethanol water being 60 ~ 90% by volume fraction carries out reflux, extract, to Fructus Akebiae seed and obtains.
As further preferred version, the ethanol extraction of described Fructus Akebiae seed is that the ethanol water being 70 ~ 80% by the volume fraction of 8 ~ 10 times of bulking values carries out reflux, extract, 1 ~ 3 time to Fructus Akebiae seed, each 1 ~ 3 hour and obtain.
Described pharmaceutical dosage forms can be any pharmaceutically useful dosage form, and these dosage forms comprise: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch; Preferred oral dosage form, as: capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum etc.Described peroral dosage form can containing conventional excipient, and such as binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, can carry out coating to tablet if desired.Suitable filler comprises cellulose, mannitol, lactose and other similar filler; Suitable disintegrating agent comprises starch, polyvinylpyrrolidone and starch derivatives, such as sodium starch glycollate; Suitable lubricant comprises, such as magnesium stearate.The suitable acceptable wetting agent of medicine comprises sodium lauryl sulphate.
The present invention adopts growth of cancer cells to breed MTT detection method, experimental demonstration Fructus Akebiae seed extract has the effect suppressing Primary hepatic carcinoma cell malignant proliferation very significantly, be expected to be applied in the preparation of the pharmaceutical preparation for the treatment of primary hepatocarcinoma as active component by suppressing Primary hepatic carcinoma cell malignant proliferation, for Fructus Akebiae seed extract has opened up a kind of new medical value.
Accompanying drawing explanation
Fig. 1 is the inhibitory action comparison diagram of each medicine group to SMMC7721 hepatoma carcinoma cell malignant proliferation, wherein: a is ordinary cells group, the G418 group of b to be Drug level be 0.6mg/mL, the ethanol extraction group of c to be Drug level the be non-seed remainder of Fructus Akebiae of 2.5mg/mL, the Fructus Akebiae seed ethanol extraction group of d to be Drug level be 2.5mg/mL.
Fig. 2 embodies the Morphology Effects (adopt the form picture being inverted mirror phase microscope (400 times) observing) of medication to hepatoma carcinoma cell of Fructus Akebiae seed extract, wherein: a figure is the SMMC7721 hepatoma carcinoma cell of cellar culture; B figure is the SMMC7721 hepatoma carcinoma cell after administration concentration is the Fructus Akebiae seed extract effect 24h of 1.88mg/mL; C figure is the SMMC7721 hepatoma carcinoma cell after administration concentration is the Fructus Akebiae seed extract effect 48h of 1.88mg/mL; D figure is the SMMC7721 hepatoma carcinoma cell after administration concentration is the Fructus Akebiae seed extract effect 72h of 1.88mg/mL.
Fig. 3 is that the Fructus Akebiae seed extract of various dose is to the inhibitory action comparison diagram of SMMC7721 hepatoma carcinoma cell malignant proliferation, wherein: a is ordinary cells group, the G418 group of b to be Drug level be 0.6mg/mL, the Fructus Akebiae seed ethanol extraction group of c to be Drug level be 1.25mg/mL, the Fructus Akebiae seed ethanol extraction group of d to be Drug level be 1.88mg/mL, the Fructus Akebiae seed ethanol extraction group of e to be Drug level be 2.5mg/mL.
Detailed description of the invention
Below in conjunction with the drawings and specific embodiments, the present invention is elaborated further.
Embodiment 1: the ethanol extraction preparing Fructus Akebiae seed and the non-seed remainder of Fructus Akebiae
Get prepared slices of Chinese crude drugs Fructus Akebiae, be separated Fructus Akebiae seed; Get Fructus Akebiae seed and each 35g of Fructus Akebiae non-seed remainder, in 60 DEG C of baking ovens, be crushed to particle diameter <0.25cm after dry 24 hours.
The volume fraction adding 350mL in the Fructus Akebiae seed of pulverizing and the granule of the non-seed remainder of Fructus Akebiae is respectively the ethanol water of 75%, and under room temperature after airtight immersion 2h, heating in water bath is to backflow, and each reflux, extract, 2h, is total to reflux, extract, 2 times; Collect ethanol extract, filter, be concentrated into 30mL respectively, regulate pH to be 7.0 with alkali, then add distilled water and be settled to 35mL(1g crude drug/mL).
The sterilizing of cell culture condition sucking filtration, respectively subpackage be stored in-80 DEG C for subsequent use.
Embodiment 2: the ethanol extraction of Fructus Akebiae seed and the non-seed remainder of Fructus Akebiae is tested the inhibitory action that Primary hepatic carcinoma cell is bred
SMMC7721 hepatoma carcinoma cell is carried out 96 orifice plate paving wares;
After overnight cell is adherent, all carry out the administration of the ethanol extraction of Fructus Akebiae seed ethanol extraction and the non-seed remainder of Fructus Akebiae with the Drug level of 2.5mg/mL; And to take concentration be the cytotoxic antibiotic G418 of 0.6mg/mL is positive control.
Respectively administration 24,48, adopt mtt assay to detect SMMC7721 hepatoma cell proliferation rate of growth after 72h, and draw amount effect curve.
Fig. 1 is the inhibitory action comparison diagram of each medicine group to SMMC7721 hepatoma carcinoma cell malignant proliferation, wherein: a is ordinary cells group, the G418 group of b to be Drug level be 0.6mg/mL, the ethanol extraction group of c to be Drug level the be non-seed remainder of Fructus Akebiae of 2.5mg/mL, the Fructus Akebiae seed ethanol extraction group of d to be Drug level be 2.5mg/mL.
From Fig. 1 comparing result: Drug level is the Fructus Akebiae seed extract of 2.5mg/mL is obviously better than the non-seed remainder of Fructus Akebiae of same medicine concentration ethanol extraction to the inhibitory action of SMMC7721 hepatoma cell proliferation, and is better than positive control drug-cytotoxic antibiotic G418 that Drug level is 0.6mg/mL.
Embodiment 3: the Fructus Akebiae seed extract of various dose is tested the inhibitory action that Primary hepatic carcinoma cell is bred
SMMC7721 hepatoma carcinoma cell is carried out 96 orifice plate paving wares;
After overnight cell is adherent, be that the Fructus Akebiae seed extract of 3 dosage of 1.25mg/mL, 1.88mg/mL, 2.5mg/mL carries out administration respectively with ultimate density; And to take concentration be the cytotoxic antibiotic G418 of 0.6mg/mL is positive control.
Respectively administration 24,48, adopt mtt assay to detect SMMC7721 hepatoma cell proliferation rate of growth after 72h, and draw amount effect curve.
Fig. 2 embodies the Morphology Effects (adopt the form picture being inverted mirror phase microscope (400 times) observing) of medication to hepatoma carcinoma cell of Fructus Akebiae seed extract; Wherein: a figure is the SMMC7721 hepatoma carcinoma cell of cellar culture; B figure is the SMMC7721 hepatoma carcinoma cell after administration concentration is the Fructus Akebiae seed extract effect 24h of 1.88mg/mL; C figure is the SMMC7721 hepatoma carcinoma cell after administration concentration is the Fructus Akebiae seed extract effect 48h of 1.88mg/mL; D figure is the SMMC7721 hepatoma carcinoma cell after administration concentration is the Fructus Akebiae seed extract effect 72h of 1.88mg/mL.
As seen from Figure 2: along with the prolongation of the action time of Fructus Akebiae seed extract, in hepatoma carcinoma cell, cavity progressively becomes large, and apoptosis phenomenon appears in part cell.
Fig. 3 is that the Fructus Akebiae seed extract of various dose is to the inhibitory action comparison diagram of SMMC7721 hepatoma carcinoma cell malignant proliferation, wherein: a is ordinary cells group, the G418 group of b to be Drug level be 0.6mg/mL, the Fructus Akebiae seed ethanol extraction group of c to be Drug level be 1.25mg/mL, the Fructus Akebiae seed ethanol extraction group of d to be Drug level be 1.88mg/mL, the Fructus Akebiae seed ethanol extraction group of e to be Drug level be 2.5mg/mL.
Comparing result from Fig. 3: when the Drug level of Fructus Akebiae seed extract is 1.25mg/mL, demonstrated the inhibitory action to SMMC7721 hepatoma cell proliferation; When Drug level is increased to 1.88mg/mL, Fructus Akebiae seed extract has been the positive controls-cytotoxic antibiotic G418 group of 0.6mg/mL close to Drug level to the inhibitory action of SMMC7721 hepatoma cell proliferation; When Drug level is increased to 2.5mg/mL, Fructus Akebiae seed extract has been better than to the inhibitory action of SMMC7721 hepatoma cell proliferation positive controls-cytotoxic antibiotic G418 group that Drug level is 0.6mg/mL.
Visible in sum: Fructus Akebiae seed ethanol extraction has inhibitory action significantly to hepatoma carcinoma cell malignant proliferation, and in dose-effect relationship, be expected to be applied to as active component in the preparation of the pharmaceutical preparation for the treatment of primary hepatocarcinoma by suppressing Primary hepatic carcinoma cell malignant proliferation, there is medical value.
Finally be necessary described herein: above embodiment is only for being described in more detail technical scheme of the present invention; can not be interpreted as limiting the scope of the invention, some nonessential improvement that those skilled in the art's foregoing according to the present invention is made and adjustment all belong to protection scope of the present invention.
Claims (3)
1. the application of Fructus Akebiae seed extract in treatment Primary Hepatic cancer drug, it is characterized in that: described Fructus Akebiae seed extract is the ethanol extraction of Fructus Akebiae seed, described application is the pharmaceutical preparation using described Fructus Akebiae seed extract as sole active agent for the preparation for the treatment of primary hepatocarcinoma.
2. apply as claimed in claim 1, it is characterized in that: the ethanol extraction of described Fructus Akebiae seed is that the ethanol water being 60 ~ 90% by volume fraction carries out reflux, extract, to Fructus Akebiae seed and obtains.
3. apply as claimed in claim 2, it is characterized in that: the ethanol extraction of described Fructus Akebiae seed is that the ethanol water being 70 ~ 80% by the volume fraction of 8 ~ 10 times of bulking values carries out reflux, extract, 1 ~ 3 time to Fructus Akebiae seed, each 1 ~ 3 hour and obtain.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310140809.XA CN103191162B (en) | 2013-04-22 | 2013-04-22 | Application of fructus akebiae extract in preparation of drug for treating primary hepatic carcinoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310140809.XA CN103191162B (en) | 2013-04-22 | 2013-04-22 | Application of fructus akebiae extract in preparation of drug for treating primary hepatic carcinoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103191162A CN103191162A (en) | 2013-07-10 |
| CN103191162B true CN103191162B (en) | 2015-04-08 |
Family
ID=48714098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310140809.XA Expired - Fee Related CN103191162B (en) | 2013-04-22 | 2013-04-22 | Application of fructus akebiae extract in preparation of drug for treating primary hepatic carcinoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103191162B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103191161A (en) * | 2013-04-22 | 2013-07-10 | 上海中医药大学 | Application of fructus akebiae extract in preparation of drug for treating primary hepatic carcinoma |
-
2013
- 2013-04-22 CN CN201310140809.XA patent/CN103191162B/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| 梅全喜.八月札.《广东地产药材研究》.广东科技出版社,2011, * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103191162A (en) | 2013-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105769891A (en) | Low-polarity rare ginsenoside mixture and application thereof | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| CN101850032A (en) | Anti-tumor traditional Chinese medicine composition and preparation method and application thereof | |
| CN103463554B (en) | A kind of treat malignant tumor pharmaceutical composition and preparation method and purposes | |
| CN103191162B (en) | Application of fructus akebiae extract in preparation of drug for treating primary hepatic carcinoma | |
| CN101084905B (en) | Application of ganoderic acid Me in tumoral growth or propagation inhibitor | |
| CN102858359B (en) | Medicinal composition comprising alcohol-soluble and water-insoluble licorice extract, pharmaceutical preparation, pharmaceutical application, therapeutic method, and preparative method thereof | |
| CN102988422A (en) | American cockroach nano extract and preparation method thereof | |
| CN103191161A (en) | Application of fructus akebiae extract in preparation of drug for treating primary hepatic carcinoma | |
| CN106344885B (en) | Pharmaceutical composition for treating non-alcoholic fatty liver disease and preparation method and application thereof | |
| CN103191428A (en) | Akebia fruit seed extractive and cytotoxin antibiotic combined composition and application thereof | |
| CN108355027A (en) | Chinese herbal medicine extract and application thereof in preparing medicine for treating triple negative breast cancer | |
| CN104069149A (en) | Method for processing traditional Chinese medicine decoction piece by using bear gall as matrix | |
| CN109966335B (en) | Anti-tumor composition | |
| CN103239569B (en) | Application of viola diffusa in preparation of medicine for treating viral hepatitis | |
| CN107375498A (en) | Anti- woman's inflammation preparation is preparing the application in treating Asherman's syndrom medicine | |
| CN108079055B (en) | Combination of traditional Chinese medicine composition and sorafenib and application of combination in preparation of medicine for treating liver cancer | |
| CN104800193A (en) | Pharmaceutical use of guaiol | |
| WO2010025621A1 (en) | Extracts of flavonoids-containing traditional chinese medicine, extraction method, pharmaceutical composition and application thereof | |
| CN107296896B (en) | Pharmaceutical composition for treating glioma and preparation method thereof | |
| CN104771454B (en) | A kind of pharmaceutical composition for the treatment of of acute radiation oral mucositis | |
| CN105853504A (en) | Anticancer drink | |
| CN105326899A (en) | Traditional Chinese medicine for treating leukoderma and preparation method for traditional Chinese medicine | |
| TWI635867B (en) | Use of herbal composition in preparation drug for inhibiting tumor cell metastasis | |
| CN105287865A (en) | Medicinal composition for treating malignant tumor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150408 Termination date: 20180422 |